Citalopram News and Research

RSS
Citalopram is an antidepressant drug used to treat major depression associated with mood disorders. It is also used on occasion in the treatment of body dysmorphic disorder and anxiety.
Anticholinergic medications associated with pneumonia risk in older people

Anticholinergic medications associated with pneumonia risk in older people

Citalopram can increase efficacy of BMSCs differentiating into neuronal-like cells

Citalopram can increase efficacy of BMSCs differentiating into neuronal-like cells

Tiny molecule may provide marker for depression

Tiny molecule may provide marker for depression

Anti-depressants could slow onset of Alzheimer's disease

Anti-depressants could slow onset of Alzheimer's disease

Antidepressant stops growth of plaques in mouse model of Alzheimer's disease

Antidepressant stops growth of plaques in mouse model of Alzheimer's disease

Antidepressant medication shows potential in treating symptoms of agitation that occur with AD

Antidepressant medication shows potential in treating symptoms of agitation that occur with AD

Enhancing the NMDA glutamate receptor causes antidepressant-like effects

Enhancing the NMDA glutamate receptor causes antidepressant-like effects

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

Seven scientists to receive Annual Klerman and Freedman Prizes from Brain & Behavior Research Foundation

Seven scientists to receive Annual Klerman and Freedman Prizes from Brain & Behavior Research Foundation

Research finds no increased risk of abnormal heart rhythms despite FDA warning against citalopram

Research finds no increased risk of abnormal heart rhythms despite FDA warning against citalopram

Alarming report on persistent side effects of antidepressant drugs published online

Alarming report on persistent side effects of antidepressant drugs published online

Proton pump inhibitors for clopidogrel patients ‘not so dangerous’

Proton pump inhibitors for clopidogrel patients ‘not so dangerous’

Paper describes novel psychotherapeutic approach in a boy with Asperger's syndrome

Paper describes novel psychotherapeutic approach in a boy with Asperger's syndrome

Health Canada announces labelling update for Cipralex

Health Canada announces labelling update for Cipralex

Interferon linked with increased risk of depression in HCV patients

Interferon linked with increased risk of depression in HCV patients

AstraZeneca, Targacept announce top-line results from remaining TC-5214 Phase 3 studies on MDD

AstraZeneca, Targacept announce top-line results from remaining TC-5214 Phase 3 studies on MDD

SSRI use raises risk of fall among elderly with dementia: Study

SSRI use raises risk of fall among elderly with dementia: Study

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 study on MDD

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 study on MDD

Switching or adding antidepressants does not exacerbate side effects

Switching or adding antidepressants does not exacerbate side effects

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD